1 00:00:00,160 --> 00:00:02,720 Speaker 1: For the last few years, there's been this drug that 2 00:00:02,960 --> 00:00:04,760 Speaker 1: everyone seems to be talking about. 3 00:00:05,000 --> 00:00:09,960 Speaker 2: Oh wow, people with type two diabetes are excited about 4 00:00:09,960 --> 00:00:12,080 Speaker 2: the potential of once weekly ozimpic. 5 00:00:12,240 --> 00:00:15,240 Speaker 1: Ozembic was approved to treat diabetes in the US in 6 00:00:15,280 --> 00:00:18,319 Speaker 1: twenty seventeen, but the effect it can have on weight 7 00:00:18,360 --> 00:00:21,319 Speaker 1: loss has become what it's most known for, and you. 8 00:00:21,239 --> 00:00:23,799 Speaker 2: May lose weight. In the same one year study, adults 9 00:00:23,840 --> 00:00:25,680 Speaker 2: lost on average up to twelve pounds. 10 00:00:25,840 --> 00:00:27,200 Speaker 3: Oh at twelve pounds. 11 00:00:27,240 --> 00:00:30,240 Speaker 1: Well, it may seem like we've been talking about ozembic forever. 12 00:00:30,760 --> 00:00:33,760 Speaker 1: My colleague Madison Muller, who writes for Bloomberg's Health Team, 13 00:00:34,159 --> 00:00:37,120 Speaker 1: says it's only really been recently that a lot of 14 00:00:37,159 --> 00:00:39,000 Speaker 1: people have been talking about this drug. 15 00:00:39,240 --> 00:00:42,120 Speaker 4: It's only been within the last five years that we've 16 00:00:42,159 --> 00:00:46,360 Speaker 4: really started hearing about ozembic, and especially within the last 17 00:00:46,600 --> 00:00:49,600 Speaker 4: year or two years that this has really taken off 18 00:00:49,600 --> 00:00:50,879 Speaker 4: in the public consciousness. 19 00:00:50,960 --> 00:00:53,280 Speaker 1: And for the last six months, Madison's been writing a 20 00:00:53,320 --> 00:00:56,440 Speaker 1: lot about ozempic and other drugs like it, like Munjaro 21 00:00:56,640 --> 00:00:57,240 Speaker 1: and Wagovi. 22 00:00:57,720 --> 00:01:01,040 Speaker 4: When I first started covering this beat the only drug 23 00:01:01,080 --> 00:01:03,000 Speaker 4: that I was really hearing about or that people were 24 00:01:03,040 --> 00:01:05,360 Speaker 4: talking about was ozempic and then a little bit of 25 00:01:05,440 --> 00:01:08,240 Speaker 4: Wigo V conversations too, But ozembic is really the drug 26 00:01:08,240 --> 00:01:10,760 Speaker 4: that started it all. I say that it's kind of 27 00:01:10,800 --> 00:01:13,440 Speaker 4: like Kleenex, like it's just become the catch all for 28 00:01:13,760 --> 00:01:15,560 Speaker 4: all of these weight loss drugs and sort of like 29 00:01:15,600 --> 00:01:16,720 Speaker 4: the whole industry. 30 00:01:17,160 --> 00:01:20,720 Speaker 1: But now, years after Ozempic was approved for use in 31 00:01:20,760 --> 00:01:24,760 Speaker 1: the US, there's a new drug that could threaten its 32 00:01:24,840 --> 00:01:28,559 Speaker 1: Kleenex like status, a drug that looks poised to steal 33 00:01:28,600 --> 00:01:31,000 Speaker 1: its market share and become the go to drug in 34 00:01:31,080 --> 00:01:34,960 Speaker 1: the space. It's called zet Bound, and it's picked up 35 00:01:34,959 --> 00:01:38,600 Speaker 1: steam on TikTok where people are sharing their experiences taking it. 36 00:01:39,120 --> 00:01:39,839 Speaker 3: Hey, it's Karen. 37 00:01:39,880 --> 00:01:42,720 Speaker 5: Here's an update my first week on zet bound after 38 00:01:42,760 --> 00:01:45,000 Speaker 5: being on wogov for over eights. 39 00:01:45,000 --> 00:01:46,680 Speaker 1: Now that I picked up my first first description on 40 00:01:46,840 --> 00:01:49,200 Speaker 1: stet bound, you guys know that I've been on manjarro. 41 00:01:49,320 --> 00:01:50,920 Speaker 3: It is going to be called zet bound, and I 42 00:01:50,960 --> 00:01:51,440 Speaker 3: do not care. 43 00:01:51,560 --> 00:01:53,280 Speaker 2: You could call it dookie on a stick and I 44 00:01:53,320 --> 00:01:54,760 Speaker 2: would still inject this. 45 00:01:55,400 --> 00:01:59,240 Speaker 1: Today on the show, how a century long pharmaceutical rivalry 46 00:01:59,440 --> 00:02:02,280 Speaker 1: gave rise to the weight loss drug craze and why 47 00:02:02,320 --> 00:02:06,080 Speaker 1: investors and analysts think this latest drug, zet Bound, could 48 00:02:06,160 --> 00:02:10,000 Speaker 1: lead its manufacturer to become the first ever trillion dollar 49 00:02:10,080 --> 00:02:13,760 Speaker 1: drug company. I'm Sarah Holder, and this is the big 50 00:02:13,800 --> 00:02:22,440 Speaker 1: take from Bloomberg News. In a lot of ways, this 51 00:02:22,520 --> 00:02:26,200 Speaker 1: story is a tale of two pharmaceutical companies, Eli Lilly 52 00:02:26,400 --> 00:02:30,520 Speaker 1: and Novo Nordisk. Both companies have been major innovators in 53 00:02:30,560 --> 00:02:33,720 Speaker 1: the treatment of diabetes and have been competitors for the 54 00:02:33,760 --> 00:02:37,160 Speaker 1: past one hundred years. But today we're going to start 55 00:02:37,200 --> 00:02:41,400 Speaker 1: with Eli Lilly, not only because it's the manufacturer of Zetbound, 56 00:02:41,840 --> 00:02:44,480 Speaker 1: but also because it's where one of the key breakthroughs 57 00:02:44,560 --> 00:02:48,520 Speaker 1: behind these types of drugs was discovered. Madison told us 58 00:02:48,600 --> 00:02:50,799 Speaker 1: she learned about it from a man named Richard D. 59 00:02:50,919 --> 00:02:51,239 Speaker 3: Marky. 60 00:02:52,760 --> 00:02:56,360 Speaker 4: Richard de Marky was a scientist at Lily for like 61 00:02:56,440 --> 00:02:57,480 Speaker 4: twenty two years. 62 00:02:58,000 --> 00:03:00,800 Speaker 1: His research looked at the body's end acrine system, which 63 00:03:00,840 --> 00:03:04,560 Speaker 1: creates and releases hormones like insulin, and he and a 64 00:03:04,600 --> 00:03:07,440 Speaker 1: collaborator filed a patent for something called. 65 00:03:07,400 --> 00:03:09,720 Speaker 3: A GLP one receptor agonist drug. 66 00:03:10,360 --> 00:03:14,240 Speaker 4: And what GLP one is, it's a gut hormone that 67 00:03:14,440 --> 00:03:17,320 Speaker 4: helps control blood sugar, helps control insulin. 68 00:03:16,960 --> 00:03:17,440 Speaker 3: In the body. 69 00:03:17,960 --> 00:03:21,200 Speaker 4: And what it also does is it mimics the effect 70 00:03:21,520 --> 00:03:25,800 Speaker 4: of eating food. So after you eat, your body releases 71 00:03:25,840 --> 00:03:29,000 Speaker 4: this GLP one hormone and it signals to the brain 72 00:03:29,120 --> 00:03:30,239 Speaker 4: that you can stop eating. 73 00:03:30,520 --> 00:03:33,760 Speaker 3: And so that's what wigovi and ozembic are. 74 00:03:35,000 --> 00:03:37,600 Speaker 1: But Demarki says when he shared this finding with his 75 00:03:37,640 --> 00:03:41,720 Speaker 1: employer Eli Lilly back in the nineties, they were not interested. 76 00:03:42,120 --> 00:03:45,440 Speaker 5: Lily knew nothing with this path but just expired, which 77 00:03:45,600 --> 00:03:49,840 Speaker 5: was a sign of the fact that they didn't believe 78 00:03:49,920 --> 00:03:54,320 Speaker 5: that obesity was a disease right, it was still a syndrome. 79 00:03:55,040 --> 00:03:57,760 Speaker 5: They honestly did not believe that people would take an 80 00:03:57,760 --> 00:04:02,480 Speaker 5: injection to treat a disease ease that was this benign Yes, 81 00:04:02,560 --> 00:04:03,640 Speaker 5: I disagree. 82 00:04:04,120 --> 00:04:06,920 Speaker 1: De Marki ended up leaving the company to continue research 83 00:04:06,960 --> 00:04:10,880 Speaker 1: into diabetes and obesity, and the patent he filed expired 84 00:04:10,920 --> 00:04:11,880 Speaker 1: in twenty seventeen. 85 00:04:12,200 --> 00:04:15,960 Speaker 4: Demarki says that after he left Lily, the interest in 86 00:04:16,040 --> 00:04:18,279 Speaker 4: obesity just sort of ceased at the company. 87 00:04:18,640 --> 00:04:21,880 Speaker 1: Jeffrey Emmick, a senior vice president for product development who'd 88 00:04:21,880 --> 00:04:25,480 Speaker 1: worked at Eli Lilly since the nineties, told Madison, quote, 89 00:04:25,680 --> 00:04:28,720 Speaker 1: we just didn't think they were going to be that efficacious. 90 00:04:29,360 --> 00:04:32,360 Speaker 1: But over in Denmark, a different approach was unfolding at 91 00:04:32,360 --> 00:04:33,240 Speaker 1: Novo Nordisk. 92 00:04:33,760 --> 00:04:38,080 Speaker 4: At Novo he had this counterpart, Lottie Knudsen, and she 93 00:04:38,480 --> 00:04:40,599 Speaker 4: is still at the company. She's still at Novo. She 94 00:04:40,600 --> 00:04:43,279 Speaker 4: has a leadership role now. And back then she was 95 00:04:43,320 --> 00:04:46,359 Speaker 4: a young scientist. This was in the nineties and she 96 00:04:46,520 --> 00:04:50,440 Speaker 4: was also interested in GLP one drugs for obesity, and 97 00:04:50,480 --> 00:04:55,600 Speaker 4: she encountered similar sort of disbelief you know, at Novo, 98 00:04:55,720 --> 00:04:59,680 Speaker 4: and they questioned her work, but she had support from 99 00:04:59,800 --> 00:05:01,839 Speaker 4: Lee Readership and that was sort of what mattered. She 100 00:05:01,880 --> 00:05:04,120 Speaker 4: got the resources that she needed to keep going with 101 00:05:04,160 --> 00:05:04,840 Speaker 4: this research. 102 00:05:05,480 --> 00:05:08,839 Speaker 1: Madison says. Novo Nordisk's research paid off more than a 103 00:05:08,880 --> 00:05:12,120 Speaker 1: decade later with a drug called Sexenda. 104 00:05:12,600 --> 00:05:15,719 Speaker 4: That was the first GLP one drug ever to be 105 00:05:16,240 --> 00:05:18,840 Speaker 4: approved by the FDA for weight loss, and that happened 106 00:05:18,880 --> 00:05:23,240 Speaker 4: in twenty fourteen, and so Novo kept going. They wanted 107 00:05:23,320 --> 00:05:26,120 Speaker 4: this drug was injected daily. They wanted a drug that 108 00:05:26,120 --> 00:05:29,039 Speaker 4: could be injected weekly, and so they were trying to 109 00:05:29,160 --> 00:05:31,640 Speaker 4: change the molecule so that it could be a weekly 110 00:05:31,680 --> 00:05:35,000 Speaker 4: injection instead of a daily injection. They changed it slightly, 111 00:05:35,080 --> 00:05:37,560 Speaker 4: like added a fatty acid chain or something to it 112 00:05:38,000 --> 00:05:41,520 Speaker 4: and the way that they changed the molecule actually led 113 00:05:41,560 --> 00:05:44,960 Speaker 4: to a lot more weight loss, so they weren't trying 114 00:05:45,200 --> 00:05:48,360 Speaker 4: still to develop a more effective weight loss drug. They 115 00:05:48,360 --> 00:05:52,719 Speaker 4: were trying to make a once weekly version, and they 116 00:05:52,760 --> 00:05:55,520 Speaker 4: came up with ozempic. Ozempic was the result of that, 117 00:05:55,600 --> 00:05:59,039 Speaker 4: and the weight loss from ozempic was just substantial, like 118 00:05:59,120 --> 00:06:02,760 Speaker 4: it was way more than sax senda. It was super effective, 119 00:06:03,440 --> 00:06:08,360 Speaker 4: and that sort of started this whole interest and obesity again. 120 00:06:09,839 --> 00:06:12,359 Speaker 1: So Novo Nordisk was out as the front runner in 121 00:06:12,400 --> 00:06:15,599 Speaker 1: the space. But remember Eli Lilly is going to become 122 00:06:15,720 --> 00:06:19,600 Speaker 1: a big player here too, They just weren't there yet. 123 00:06:20,040 --> 00:06:23,120 Speaker 1: While Novo Nordisk was working on ozepik, Eli Lilly was 124 00:06:23,160 --> 00:06:25,719 Speaker 1: actually focused on treating a very different disease. 125 00:06:26,320 --> 00:06:28,560 Speaker 4: They were at the time of like twenty fourteen to 126 00:06:28,600 --> 00:06:34,040 Speaker 4: twenty seventeen, really focused on Alzheimer's. They had for decades 127 00:06:34,160 --> 00:06:37,760 Speaker 4: poured billions of dollars into Alzheimer's research, so they were 128 00:06:38,600 --> 00:06:41,360 Speaker 4: really hopeful about this, and all of those trials ended 129 00:06:41,400 --> 00:06:45,520 Speaker 4: up being failures, like really expensive, disappointing failures. 130 00:06:45,960 --> 00:06:49,080 Speaker 1: So right around twenty seventeen, Novo Nordisk is out ahead 131 00:06:49,080 --> 00:06:51,719 Speaker 1: with ozempic, and Eli Lilly is on its back foot, 132 00:06:51,839 --> 00:06:55,080 Speaker 1: licking its wounds from its Alzheimer's flops. When Eli Lilly 133 00:06:55,080 --> 00:06:58,559 Speaker 1: brings in a new CEO, dave Rix, and right away 134 00:06:58,800 --> 00:07:00,680 Speaker 1: he made weight loss drugs a priority. 135 00:07:01,120 --> 00:07:05,320 Speaker 4: He sent his top scientists to go basically do a 136 00:07:05,360 --> 00:07:08,279 Speaker 4: short stint in diabetes research to see what he could find, 137 00:07:08,360 --> 00:07:11,800 Speaker 4: see if he could find promising research. And he did, 138 00:07:11,920 --> 00:07:14,280 Speaker 4: I mean pretty much right away. He found this small 139 00:07:14,320 --> 00:07:19,120 Speaker 4: study of trizeppetide, which is a GLP one drug combined 140 00:07:19,120 --> 00:07:23,000 Speaker 4: with another gut hormone called GIP and there was this 141 00:07:23,040 --> 00:07:27,000 Speaker 4: small study done in healthy people in Singapore just to 142 00:07:27,040 --> 00:07:30,600 Speaker 4: see if the drug was safe or not. And what 143 00:07:30,640 --> 00:07:33,200 Speaker 4: they saw was that people in this study lost so 144 00:07:33,320 --> 00:07:35,480 Speaker 4: much weight that they had to drop out of the study. 145 00:07:35,760 --> 00:07:38,600 Speaker 1: That study was a good start, but Eli Lilly still 146 00:07:38,640 --> 00:07:40,000 Speaker 1: had to make up for lost time. 147 00:07:40,200 --> 00:07:43,000 Speaker 4: They knew that they needed to do this as fast 148 00:07:43,000 --> 00:07:45,080 Speaker 4: as they possibly could, to get a drug on the 149 00:07:45,120 --> 00:07:48,360 Speaker 4: market as fast as they could, because drug development can 150 00:07:48,400 --> 00:07:51,480 Speaker 4: take a really long time, like it can take six 151 00:07:51,560 --> 00:07:53,840 Speaker 4: to eight years, even a decade, and they didn't really 152 00:07:53,880 --> 00:07:54,680 Speaker 4: have that time. 153 00:07:55,520 --> 00:07:59,080 Speaker 3: Zembic was already out there. They needed to do this quickly. 154 00:07:59,200 --> 00:08:03,520 Speaker 4: And so what Dan Skavronsky, who is now the chief 155 00:08:03,560 --> 00:08:07,000 Speaker 4: scientific and chief medical officer at Lily, told me was 156 00:08:07,040 --> 00:08:11,200 Speaker 4: that he basically told the scientists to go forth with 157 00:08:11,240 --> 00:08:14,280 Speaker 4: the innovation, do things quickly, and he kind of like 158 00:08:14,520 --> 00:08:18,560 Speaker 4: freed them from the bureaucratic processes that can bog down 159 00:08:18,640 --> 00:08:21,920 Speaker 4: drug development at a big company like Lily. And yeah, 160 00:08:21,920 --> 00:08:25,240 Speaker 4: I mean, these scientists just went really fast. They got 161 00:08:25,240 --> 00:08:28,000 Speaker 4: a drug on the market quickly, They did these trials quickly. 162 00:08:28,040 --> 00:08:31,760 Speaker 4: They also went straight from a diabetes trial into a 163 00:08:31,800 --> 00:08:33,160 Speaker 4: late stage obesity trial. 164 00:08:33,200 --> 00:08:35,400 Speaker 3: They worked with the FDA to speed up the process 165 00:08:35,400 --> 00:08:36,120 Speaker 3: a little bit too. 166 00:08:36,960 --> 00:08:40,800 Speaker 4: And yeah, and then Manduro was approved for diabetes in 167 00:08:40,880 --> 00:08:43,720 Speaker 4: twenty twenty two, and zet Bound was approved for weight 168 00:08:43,760 --> 00:08:44,520 Speaker 4: loss last year. 169 00:08:45,520 --> 00:08:48,880 Speaker 1: After the break, What set Zetbound apart and why it 170 00:08:48,960 --> 00:08:53,000 Speaker 1: could make Eli Lilly the first ever trillion dollar drug company. 171 00:09:01,480 --> 00:09:02,040 Speaker 3: We're back. 172 00:09:02,679 --> 00:09:05,120 Speaker 1: When we left off, Eli Lelly had just brought its 173 00:09:05,200 --> 00:09:07,920 Speaker 1: new drug, zet Bound, to market, but it was still 174 00:09:08,080 --> 00:09:11,560 Speaker 1: years behind Novo Nordisk and ozempic. Is it a big 175 00:09:11,760 --> 00:09:14,640 Speaker 1: advantage for a drug manufacturer to be first to market? 176 00:09:14,960 --> 00:09:17,760 Speaker 4: So you would think so, and in some cases it is, 177 00:09:17,920 --> 00:09:23,320 Speaker 4: But you know, It's unlike other industries where innovating too 178 00:09:23,440 --> 00:09:27,280 Speaker 4: late is could be a death sentence for some companies. 179 00:09:28,080 --> 00:09:31,320 Speaker 4: In the drug industry, what we see is that being 180 00:09:31,360 --> 00:09:34,840 Speaker 4: first to the market has an advantage, but ultimately just 181 00:09:34,920 --> 00:09:39,560 Speaker 4: having the best drug is what can set a pharmaceutical 182 00:09:39,559 --> 00:09:40,320 Speaker 4: company apart. 183 00:09:40,600 --> 00:09:42,720 Speaker 1: Madison told me, one of the key things to know 184 00:09:42,760 --> 00:09:46,079 Speaker 1: about zetbound is that it works slightly differently than its 185 00:09:46,120 --> 00:09:47,560 Speaker 1: main competitors. 186 00:09:47,240 --> 00:09:51,560 Speaker 4: Ozepic and Wigovi are GLP one receptor agonist drug, and 187 00:09:51,640 --> 00:09:54,040 Speaker 4: so what scientists are starting to realize is that by 188 00:09:54,120 --> 00:09:59,280 Speaker 4: like layering and combining other hormones or other sort of 189 00:09:59,360 --> 00:10:03,320 Speaker 4: molecules with GLP one, you can get even more weight loss. 190 00:10:03,559 --> 00:10:07,640 Speaker 4: And so that's what zetbound is. It's a combination of 191 00:10:07,720 --> 00:10:12,240 Speaker 4: GLP one and another gut hormone called GIP and what 192 00:10:12,280 --> 00:10:15,160 Speaker 4: we see with that is that the weight loss can 193 00:10:15,200 --> 00:10:18,880 Speaker 4: reach up to like twenty one percent, and the weight 194 00:10:18,920 --> 00:10:21,600 Speaker 4: loss that you see from wagovi tops out at around 195 00:10:21,640 --> 00:10:24,760 Speaker 4: fifteen percent. And Lily has another drug in the works 196 00:10:24,760 --> 00:10:27,880 Speaker 4: that combines three different gut hormones and that one is 197 00:10:28,080 --> 00:10:30,120 Speaker 4: up to a third of your body weight. 198 00:10:30,120 --> 00:10:31,440 Speaker 3: Is what patients are losing. 199 00:10:31,520 --> 00:10:35,320 Speaker 4: So it's sort of like by layering or combining different 200 00:10:35,360 --> 00:10:37,679 Speaker 4: hormones together, you can get even more weight loss, which 201 00:10:37,720 --> 00:10:39,439 Speaker 4: is sort of what we're seeing with zetbound. 202 00:10:39,760 --> 00:10:42,720 Speaker 1: As for what this new drug means for Zepbound's parent company, 203 00:10:42,800 --> 00:10:46,520 Speaker 1: Eli Lilly, Madison told us there's this new acronym that's 204 00:10:46,559 --> 00:10:48,319 Speaker 1: popping up among investors. 205 00:10:48,679 --> 00:10:52,880 Speaker 4: One of the analysts told me that JBL, which stands 206 00:10:52,920 --> 00:10:56,760 Speaker 4: for just by Lily, is this new acronym that some 207 00:10:56,920 --> 00:11:00,520 Speaker 4: investors that he's spoken to are saying there's like no 208 00:11:00,760 --> 00:11:03,840 Speaker 4: limit in how high its stock will go, that it's 209 00:11:03,960 --> 00:11:07,160 Speaker 4: just going to continue growing. It has a price earnings 210 00:11:07,240 --> 00:11:11,040 Speaker 4: ratio of around fifty right now, which is really unheard 211 00:11:11,080 --> 00:11:12,600 Speaker 4: of for a pharma company. 212 00:11:13,000 --> 00:11:16,280 Speaker 1: If Eli Lily continues on the trajectory that Wall Street 213 00:11:16,320 --> 00:11:19,160 Speaker 1: expects it to, how much could it be worth. 214 00:11:19,360 --> 00:11:23,640 Speaker 4: If Eli Lilly continues on its current growth trajectory, there 215 00:11:23,720 --> 00:11:27,319 Speaker 4: are expectations, I guess that it could become the first 216 00:11:27,559 --> 00:11:31,800 Speaker 4: ever trillion dollar drug company. And there are expectations that 217 00:11:32,120 --> 00:11:35,960 Speaker 4: its current valuation implies that zeb bound could bring in 218 00:11:36,160 --> 00:11:39,720 Speaker 4: seventy billion dollars by twenty thirty just one drug alone. 219 00:11:39,880 --> 00:11:42,480 Speaker 1: The growth of drugs like zepbound and MCGOV has meant 220 00:11:42,559 --> 00:11:46,199 Speaker 1: real money for pharmaceutical companies, but their long term success 221 00:11:46,240 --> 00:11:49,440 Speaker 1: will depend on how many people take them. Some people 222 00:11:49,520 --> 00:11:52,040 Speaker 1: are deterred by the unpleasant side effects of these drugs, 223 00:11:52,360 --> 00:11:54,440 Speaker 1: and some are turned off by the price, which can 224 00:11:54,520 --> 00:11:57,199 Speaker 1: run upwards of one thousand dollars a month in the US, 225 00:11:58,000 --> 00:12:01,319 Speaker 1: and a lot of private insurers don't cover them well. 226 00:12:01,559 --> 00:12:04,800 Speaker 1: After doing all this reporting, what are your takeaways from 227 00:12:05,000 --> 00:12:08,760 Speaker 1: the story of Lily and Novo and what will you 228 00:12:08,840 --> 00:12:10,040 Speaker 1: be watching for next? 229 00:12:10,320 --> 00:12:14,520 Speaker 4: Yeah, I think the story between the competition between Lily 230 00:12:14,640 --> 00:12:16,880 Speaker 4: and Novo is not over yet, and it's going to 231 00:12:16,920 --> 00:12:19,840 Speaker 4: continue for the next decade or even longer. 232 00:12:19,880 --> 00:12:21,120 Speaker 3: And what I'm. 233 00:12:21,240 --> 00:12:24,120 Speaker 4: Curious to see is sort of how other drug makers 234 00:12:24,160 --> 00:12:27,480 Speaker 4: now enter this race and who's going to be next. 235 00:12:27,559 --> 00:12:30,199 Speaker 4: You know, which product ultimately will win, because it might 236 00:12:30,240 --> 00:12:32,960 Speaker 4: not be one of Lily or Novo's. I mean, Amjin 237 00:12:33,080 --> 00:12:36,439 Speaker 4: is developing a shot that's taken once a month, and 238 00:12:37,200 --> 00:12:40,719 Speaker 4: experts are really excited about that because the prospect of 239 00:12:40,760 --> 00:12:43,600 Speaker 4: a drug being taken less frequently is very enticing and 240 00:12:44,400 --> 00:12:49,240 Speaker 4: would likely be also attractive to patients. And so there 241 00:12:49,280 --> 00:12:51,720 Speaker 4: are these other drugs that are and other companies that 242 00:12:51,760 --> 00:12:55,080 Speaker 4: are sort of circling, and you know, on the cusp 243 00:12:55,120 --> 00:12:58,040 Speaker 4: of they're still a little bit further behind Lillian Novo, 244 00:12:58,120 --> 00:13:00,760 Speaker 4: But it will be interesting to see what's now and 245 00:13:01,000 --> 00:13:02,640 Speaker 4: how this continues to play out. 246 00:13:03,280 --> 00:13:07,760 Speaker 1: Thank you so much, Madison, Thank you, thanks for listening 247 00:13:07,840 --> 00:13:10,920 Speaker 1: to the Big Take from Bloomberg News. I am Sarah Holder. 248 00:13:11,640 --> 00:13:14,679 Speaker 1: This episode was produced by David Fox. It was edited 249 00:13:14,720 --> 00:13:18,000 Speaker 1: by Caitlin Kenney and Rebecca Greenfield. It was mixed by 250 00:13:18,040 --> 00:13:21,760 Speaker 1: Alex Suguiera. It was fact checked by Tiffany Choi. Our 251 00:13:21,840 --> 00:13:25,280 Speaker 1: senior producers are Naomi Shaven and Jill Duddy Carly. We 252 00:13:25,320 --> 00:13:29,800 Speaker 1: get editorial direction from Elizabeth Ponso. Nicole Beemsterborr is our 253 00:13:29,840 --> 00:13:34,000 Speaker 1: executive producer. Sage Bauman is our head of podcasts Special 254 00:13:34,000 --> 00:13:37,400 Speaker 1: Thanks to Madison Muller for her reporting. Thanks for tuning in. 255 00:13:37,800 --> 00:13:39,040 Speaker 1: We'll be back tomorrow.